SGFG
AZN icon

Silver Grove Financial Group’s AstraZeneca AZN Stock Holding History

Silver Grove Financial Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.5K Buy
+398
New +$74.9K 0.04% 306

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Silver Grove Financial Group's AZN Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in AstraZeneca (AZN) in Q2 2026: 398 shares worth $75.5K. The stake represents 0.04% of the portfolio and ranks #306 among its holdings.

1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Silver Grove Financial Group held 398 shares of AstraZeneca worth $75.5K as of Q2 2026.
  • AstraZeneca was a new Silver Grove Financial Group position in Q2 2026.
  • AstraZeneca made up 0.04% of Silver Grove Financial Group's portfolio in Q2 2026, its #306 holding.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.